title: Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
abstract: OBJECTIVE
  To evaluate the safety, tolerability, and benefit of fluvoxamine for the treatment of major depressive disorder or anxiety disorders in children and adolescents with cancer.
  
  
  METHODS
  The study was conducted from 2001 to 2004 at a pediatric hematology-oncology center. Fifteen children and adolescents with cancer were treated with fluvoxamine 100 mg/day in an open prospective 8-week trial. Safety and tolerability were evaluated at baseline and at weeks 4 and 8 by blood tests and the Side Effects Checklist. Clinical benefit was assessed with the Clinical Global Impressions-Improvement, the Children's Depression Rating Scale-Revised, and the Pediatric Anxiety Rating Scale.
  
  
  RESULTS
  Fluvoxamine was well tolerated by all subjects. Psychiatric symptoms improved significantly.
  
  
  CONCLUSIONS
  In this open trial, fluvoxamine appeared to be well tolerated and was associated with a promising reduction in the depression and anxiety symptoms of pediatric patients with cancer.
authors.affiliation: Feinberg Department of Child Psychiatry, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel. gothelf@post.tau.ac.il
authors.forename: Doron
authors.initials: D
authors.lastname: Gothelf
authors.forename: Maly
authors.initials: M
authors.lastname: Rubinstein
authors.forename: Eyal
authors.initials: E
authors.lastname: Shemesh
authors.forename: Orit
authors.initials: O
authors.lastname: Miller
authors.forename: Ilana
authors.initials: I
authors.lastname: Farbstein
authors.forename: Anat
authors.initials: A
authors.lastname: Klein
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
authors.forename: Alan
authors.initials: A
authors.lastname: Apter
authors.forename: Isaac
authors.initials: I
authors.lastname: Yaniv
mesh_terms: D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D016666:Fluvoxamine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D009369:Neoplasms / Q000523:psychology*; D010865:Pilot Projects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012803:Sick Role
chemical_list: D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors